When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

Alexion has routinely featured among lists of top biopharma takeover prospects in the last couple of years, and that was a good call – AstraZeneca has just swooped in with $39 billion cash-and ...

Alexion Pharmaceuticals Inc. could later be ordered to pay more in damages for another claim in which Zurn ruled against it, ...

"The proposed acquisition will bolster the Alexion, AstraZeneca Rare Disease late-stage pipeline and expand on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601 ...

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 ...

Despite failing in ALS, Alexion, recently acquired by AstraZeneca, brings additional clinical-stage programs for rare diseases. The FDA approved Apellis Pharmaceuticals drug pegcetacoplan ...

Drug giant AstraZeneca’s shares “fell sharply” this week after it agreed to “the biggest deal in its history”, says Julia Kollewe in The Guardian. Investors are worried that the $39bn it ...

On August 30, 2024, Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) and Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) settled their ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...

U.S. Consumer Prices Up 0.2%, Core Inflation Exceeds ExpectationsWed, 11 Sep 2024 13:28:21 GMT Fed’s Dilemma: Will Today’s CPI Data Tip the Inflation-Jobs Balance?Wed, 11 Sep 2024 11:42:20 GMT ...

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals for $39 billion, a deal aimed at boosting AstraZeneca's immunology and rare-disease research, combining the companies ...